DLA Piper has advised Kartos Therapeutics. Kartos Therapeutics, a US-based clinical stage biotechnology company, has entered into an agreement to be acquired by the French biopharmaceutical...
Ipsen Acquires Kartos Therapeutics in US$1.75 Billion Deal
Gossamer Bio Announces Exchange Offer and Consent Solicitation for Convertible Senior Notes
DLA Piper has advised Cantor Fitzgerald & Co. Gossamer Bio, Inc., a biopharmaceutical company focused on developing treatments for pulmonary hypertension, has completed an exchange offer...
Dentsply Sirona Completes $550 Million Notes Offering
Paul Hastings has advised Goldman Sachs as sole book-running manager and administrative agent, and DLA Piper has served as special counsel to Dentsply Sirona Inc. Dentsply...
Owlet’s $11.6 Million Common Stock Offering
Latham & Watkins advised Owlet in the offering, and DLA Piper advised Titan Partners Group, as underwriter. Owlet, Inc. (NYSE:OWLT), the pioneer of smart infant monitoring,...
Zura Bio’s Warrant Exchange Offer and Consent Solicitation
DLA Piper advised Cantor Fitzgerald on the transaction. The transaction consisted in an offer to exchange certain outstanding warrants to purchase Class A ordinary shares of...
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Elicio, while DLA Piper advised JonesTrading Institutional Services (Jones), as agent and as sole book-running manager in the...
Custom Health’s Business Combination with Berenson Acquisition Corp.
DLA Piper advised Custom Health Inc., while Greenberg Traurig advised Berenson Acquisition Corp. on the deal. Custom Health Inc, a digital healthcare firm, announced its business...
Axsome Therapeutics’ US$225 Million Shares Public Offering
DLA Piper advised Axsome Therapeutics on the offering. Axsome Therapeutics, Inc. (Axsome), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Iovance Biotherapeutics’ $200 Million Acquisition of Proleukin
DLA Piper advised Iovance Biotherapeutics in the deal. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced its definitive agreement with Clinigen Limited to acquire Proleukin® (aldesleukin), an interleukin-2...
Axsome Therapeutics’ Acquisition of Sunosi
DLA Piper represented Axsome Therapeutics in the transaction. Axsome Therapeutics, a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced...